Trump's remarks came a day before the Fed was set to announce its next decision on interest rates.Politicsread more
The U.S. and China have imposed tariffs on billions of dollars' worth of one another's goods since the start of 2018.Traderead more
More and more American firms are calling for the Trump administration to resolve its conflict with China.World Economyread more
In a tweet, Trump said that he and Xi "had a very good telephone conversation," and that "our respective teams will begin talks prior to our meeting."Politicsread more
China is reducing support for its electric carmakers a move experts and industry insiders warn could lead to consolidation and waning investor appetite. But some of the...Technologyread more
Is your CEO on the list? Glassdoor has the results.Power Playersread more
Joseph Gaspar, the chief financial officer at Elbit Systems, said M&A among firms in the sector began to pick up pace in the 1980s and looks set to continue.Paris Air Showread more
Stocks in Asia rose on Wednesday following positive developments overnight on the U.S.-China trade front.Asia Marketsread more
The U.S. Department of Defense has hit back at Russian officials who have criticized a U.S. plan to deploy more troops to the Middle East.World Politicsread more
Signs of companies moving out of Hong Kong have emerged, members of the business community told CNBC following massive protests in the city. But one analyst said Hong Kong's...China Politicsread more
The European Central Bank's (ECB) vice president said another large bond-buying program could be an option if inflation in the region doesn't reach its intended target.Europe Newsread more
India-based generic drugmaker Ranbaxy Laboratories has issued a recall of generic versions of the cholesterol drug Lipitor in the U.S. because of potential dosage issues, The Wall Street Journal reported Friday.
The company recalled more than 64,000 bottles of 10-milligram tablets of atorvastatin calcium—the active ingredient in Lipitor—saying some bottles could possibly contain a higher dose, the U.S. Food and Drug Administration said in a note.
Ranbaxy confirmed the recall on Friday, noting that the recall started in mid-January. Notice of the recall was posted on the FDA's website this week.
The company, which makes ingredients for drugs used in oncology, dermatology, gastrointestinal and cardiovascular disorders, generated 36 percent of its sales in the U.S. in the quarter ended in December.
Last month, Ranbaxy suspended shipments of pharmaceutical ingredients from two plants amid growing scrutiny of its manufacturing processes by regulators.
The suspension affected supplies to other key markets such as Europe and India, two people with direct knowledge of the matter said.
—By CNBC with Reuters.